The FDA's new program could expedite Orforglipron's approval, reducing review time to 1-2 months for high-burden condition treatments. Orforglipron, a non-peptide oral GLP-1 receptor agonist, has ...

Electric air taxis will soon take to the skies across the United States, thanks to a new program launched by the Department of Transportation aimed at fast-tracking the testing of the aircraft. The ...

Alnodesertib, combined with irinotecan, targets ATM-negative metastatic colorectal cancer, showing promise in the STELLA study with favorable safety and clinical activity. The FDA's fast track ...

The White House is moving quickly to deliver student debt relief to millions of American borrowers, shifting a process that once felt abstract into something borrowers can actually plan around. The ...

MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...